Stocklytics Platform
Asset logo for symbol RXRX
Recursion Pharmaceuticals
RXRX53
$6.32arrow_drop_down6.23%-$0.41
Asset logo for symbol RXRX
RXRX53

$6.32

arrow_drop_down6.23%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Recursion Pharmaceuticals (RXRX) Stocklytics Forecast

Recursion Pharmaceuticals, Inc. (RXRX) is a promising biotechnology company that specializes in drug discovery through the use of artificial intelligence and machine learning algorithms. With a focus on developing innovative therapies for a range of diseases, Recursion Pharmaceuticals has garnered significant attention in the industry. As investors look to predict the future performance of RXRX stock, it is important to consider various factors.
One key aspect to analyze is the stock price forecast for Recursion Pharmaceuticals. Based on current trends and market conditions, experts predict a positive outlook for RXRX stock in the coming years. The use of advanced technologies such as AI and machine learning in drug discovery positions Recursion Pharmaceuticals as a frontrunner in the industry. This technological edge is likely to contribute to the company's growth and subsequent increase in stock value.
add Recursion Pharmaceuticals to watchlist

Keep an eye on Recursion Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Recursion Pharmaceuticals (RXRX) stock?

Analysts have set a target price of $15 for Recursion Pharmaceuticals (RXRX), based on forecasts from 26 analysts. The predicted price range extends from a high of $33 to a low of $7. This represents a potential increase of up to 422.15% and a decrease of 10.76% from the current price of $6.32. These forecasts are as of 2022 Mar 24.
help

What are the analyst ratings for Recursion Pharmaceuticals (RXRX) stock?

The analyst ratings for Recursion Pharmaceuticals (RXRX) are distributed as follows: 2 analysts recommend buying, 6 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 8 analysts leans towards a neutral rating. These ratings indicate the general sentiment among the analysts covering Recursion Pharmaceuticals.
help

What is the AI price prediction for Recursion Pharmaceuticals (RXRX) stock?

At present, there is no AI or machine-learning-based price prediction available for Recursion Pharmaceuticals (RXRX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level